Skip to main content
Free trial

Analyze this stock with AI

Ask AI to research recent events and build a visual report.

Tell your AI:

“Help me set up FinLab and analyze IBRX ImmunityBio, Inc.: https://finlab.finance/en/setup?stock=IBRX”

Run AI in browser

IBRX

ImmunityBio, Inc. Healthcare As of 2026-06-18
Quality Weak
Valuation Cheaper
Risk High vol
Active signals Active Top-quintile 6-month momentum
7.36 Close (USD)
-0.81% 60-day
  • Quality is weaker than peers. Operating margin is only around the 10th percentile. TTM ROE is about 98.2%.
  • Valuation is cheaper than most peers. TTM P/E is in the 18th percentile, lower than most liquid US common stocks.
  • Recent volatility is elevated. 60-day annualized volatility is in the 84th percentile. Average 20-day dollar volume is about $97.6M.
  • Signals are active now. Top-quintile 6-month momentum currently holds; the tables below show what followed in this stock’s own history.

Factor profile

Factor radar Good Valuation
69
ValuationQualityGrowthMomentumRisk / liquidity

Valuation

Indicators in this group are ranked by market percentile; lower valuation and volatility are better.

69 Good
TTM P/E -8.62
Cheap
Price / book -8.69
Cheap
Free-cash-flow yield (%) -3.94
Average

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 98.13559322033898%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

17 historical occurrences (since 2016-09-15)
Average forward return after Top-quintile 6-month momentum。20-day: Win 47.1%, Sample 17, Median -1.74%, Excess +13.16%, Beat mkt rate 35.3%；60-day: Win 41.2%, Sample 17, Median -5.16%, Excess +29.28%, Beat mkt rate 41.2%；120-day: Win 37.5%, Sample 16, Median -36.14%, Excess +33.56%, Beat mkt rate 37.5%

120 days after: historical avg +43.52%

20-day +14.05%
60-day +35.17%
120-day +43.52%
20-day
60-day
120-day
Win
47.1%
41.2%
37.5%
Sample
17
17
16
Median
-1.74%
-5.16%
-36.14%
Excess
+13.16%
+29.28%
+33.56%
Beat mkt rate
35.3%
41.2%
37.5%

Over 16 occurrences, 120-day forward avg gained 43.52%, beat the market by 33.56 pts; win rate 37.5%.

Market-wide momentum baseline

Across 94,737 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.40%, a 58.3% positive-return rate, and +3.10 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

7 times historically; 60-day forward avg +43.91%, win rate 57.1%, beating the market by +39.05 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

14 times historically; 60-day forward avg +33.42%, win rate 57.1%, beating the market by +29 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

19 times historically; 60-day forward avg +38.31%, win rate 31.6%, beating the market by +34.32 pts on average.

Free trial

Analyze this stock with AI

Ask AI to research recent events and build a visual report.

Tell your AI:

“Help me set up FinLab and analyze IBRX ImmunityBio, Inc.: https://finlab.finance/en/setup?stock=IBRX”

Run AI in browser

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.